Arcus Biosciences Stock Today

RCUS Stock  USD 18.88  0.67  3.68%   

Performance

1 of 100

 
Low
 
High
Weak

Odds Of Distress

Less than 19

 
100  
 
Zero
Low
Arcus Biosciences is selling for under 18.88 as of the 29th of March 2024; that is 3.68 percent increase since the beginning of the trading day. The stock's lowest day price was 18.18. Arcus Biosciences has less than a 19 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Arcus Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of February 2024 and ending today, the 29th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
15th of March 2018
Category
Healthcare
Classification
Health Care
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company was incorporated in 2015 and is headquartered in Hayward, California. Arcus Biosciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. The company has 90.86 M outstanding shares of which 7.98 M shares are at this time shorted by private and institutional investors with about 7.57 trading days to cover. More on Arcus Biosciences

Arcus Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Arcus Biosciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Arcus Biosciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ChairmanTerry Rosen
Old NameRCUS
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, SP Small-Cap 600, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Arcus Biosciences report their recommendations after researching Arcus Biosciences' financial statements, talking to executives and customers, or listening in on Arcus Biosciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Arcus Biosciences. The Arcus consensus assessment is calculated by taking the average forecast from all of the analysts covering Arcus Biosciences.
Arcus Biosciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Arcus Biosciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Arcus Biosciences' financial leverage. It provides some insight into what part of Arcus Biosciences' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Arcus Biosciences' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Arcus Biosciences deploys its capital and how much of that capital is borrowed.
Liquidity
Arcus Biosciences cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 11 M in liabilities with Debt to Equity (D/E) ratio of 0.17, which may suggest the company is not taking enough advantage from borrowing. Arcus Biosciences has a current ratio of 6.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Arcus Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Arcus Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arcus Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arcus to invest in growth at high rates of return. When we think about Arcus Biosciences' use of debt, we should always consider it together with cash and equity.

Other Cashflows From Financing Activities

203.7 Million
Arcus Biosciences (RCUS) is traded on New York Stock Exchange in USA. It is located in 3928 Point Eden Way, Hayward, CA, United States, 94545 and employs 577 people. Arcus Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.65 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arcus Biosciences's market, we take the total number of its shares issued and multiply it by Arcus Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Arcus Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 90.86 M outstanding shares of which 7.98 M shares are at this time shorted by private and institutional investors with about 7.57 trading days to cover. Arcus Biosciences currently holds about 1.05 B in cash with (306 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.48.
Check Arcus Biosciences Probability Of Bankruptcy
Ownership Allocation
Arcus Biosciences holds a total of 90.86 Million outstanding shares. Over half of Arcus Biosciences' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Arcus Biosciences. Please watch out for any change in the institutional holdings of Arcus Biosciences as this could mean something significant has changed or is about to change at the company. Also note that nearly nine hundred eight thousand six hundred fourty-eight invesors are currently shorting Arcus Biosciences expressing very little confidence in its future performance.
Check Arcus Ownership Details

Arcus Stock Price Odds Analysis

Attributed to a normal probability distribution, the odds of Arcus Biosciences jumping above the current price in 90 days from now is about 18.06%. The Arcus Biosciences probability density function shows the probability of Arcus Biosciences stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 3.0866 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Arcus Biosciences will likely underperform. Additionally, arcus Biosciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 18.88HorizonTargetOdds Above 18.88
81.83%90 days
 18.88 
18.06%
Based on a normal probability distribution, the odds of Arcus Biosciences to move above the current price in 90 days from now is about 18.06 (This Arcus Biosciences probability density function shows the probability of Arcus Stock to fall within a particular range of prices over 90 days) .

Arcus Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Arcus Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arcus Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arcus Biosciences' value.
InstituionRecorded OnShares
Goldman Sachs Group Inc2023-12-31
1.2 M
Geode Capital Management, Llc2023-12-31
1.1 M
Woodline Partners Lp2023-12-31
M
Suvretta Capital Management, Llc2023-12-31
957.3 K
Decheng Capital Llc2023-12-31
869.8 K
Morgan Stanley - Brokerage Accounts2023-12-31
701.4 K
Bnp Paribas Investment Partners Sa2023-12-31
539.7 K
Northern Trust Corp2023-12-31
524.7 K
Balyasny Asset Management Llc2023-12-31
515.5 K
Blackrock Inc2023-12-31
10 M
Fmr Inc2023-12-31
4.7 M
View Arcus Biosciences Diagnostics

Arcus Biosciences Historical Income Statement

Arcus Biosciences Income Statement is one of the three primary financial statements used for reporting Arcus's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Arcus Biosciences revenue and expense. Arcus Biosciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Arcus Biosciences' Tax Provision is comparatively stable compared to the past year. View More Fundamentals

Arcus Stock Against Markets

Picking the right benchmark for Arcus Biosciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Arcus Biosciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Arcus Biosciences is critical whether you are bullish or bearish towards Arcus Biosciences at a given time. Please also check how Arcus Biosciences' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Arcus Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Forecasting Now

   

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
All  Next Launch Module

Arcus Biosciences Corporate Directors

Arcus Biosciences corporate directors refer to members of an Arcus Biosciences board of directors. The board of directors generally takes responsibility for the Arcus Biosciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Arcus Biosciences' board members must vote for the resolution. The Arcus Biosciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Patrick MachadoIndependent DirectorProfile
David BeierIndependent DirectorProfile
Antoni RibasIndependent DirectorProfile
Andrew PerlmanIndependent DirectorProfile

How to buy Arcus Stock?

Before investing in Arcus Biosciences, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Arcus Biosciences. To buy Arcus Biosciences stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Arcus Biosciences. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Arcus Biosciences stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Arcus Biosciences stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Arcus Biosciences stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Arcus Biosciences, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.

Already Invested in Arcus Biosciences?

The danger of trading Arcus Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arcus Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arcus Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arcus Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Arcus Biosciences is a strong investment it is important to analyze Arcus Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arcus Biosciences' future performance. For an informed investment choice regarding Arcus Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Complementary Tools for Arcus Stock analysis

When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Global Correlations
Find global opportunities by holding instruments from different markets
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Bonds Directory
Find actively traded corporate debentures issued by US companies
Is Arcus Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcus Biosciences. If investors know Arcus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcus Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.15)
Revenue Per Share
1.581
Quarterly Revenue Growth
(0.09)
Return On Assets
(0.17)
Return On Equity
(0.55)
The market value of Arcus Biosciences is measured differently than its book value, which is the value of Arcus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcus Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcus Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcus Biosciences' market value can be influenced by many factors that don't directly affect Arcus Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcus Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcus Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcus Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.